Publication | Open Access

Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease

Translational MedicineNeurodegenerative DiseasesWeight LossSubstantia NigraNitrosative StressMedicineNigral TargetingNeuropharmacologyNeuroprotectionNeurologyPharmacotherapyPharmacologyNovel Therapy